ATE346058T1 - Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon - Google Patents
Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davonInfo
- Publication number
- ATE346058T1 ATE346058T1 AT03701228T AT03701228T ATE346058T1 AT E346058 T1 ATE346058 T1 AT E346058T1 AT 03701228 T AT03701228 T AT 03701228T AT 03701228 T AT03701228 T AT 03701228T AT E346058 T1 ATE346058 T1 AT E346058T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- production
- pharmaceutical formulations
- formulations containing
- glucocorticoid mimetics
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34848602P | 2002-01-14 | 2002-01-14 | |
| US37907802P | 2002-05-09 | 2002-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE346058T1 true ATE346058T1 (de) | 2006-12-15 |
Family
ID=26995749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03701228T ATE346058T1 (de) | 2002-01-14 | 2003-01-03 | Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6960581B2 (de) |
| EP (1) | EP1467982B8 (de) |
| JP (1) | JP2005519897A (de) |
| AT (1) | ATE346058T1 (de) |
| AU (1) | AU2003202216A1 (de) |
| CA (1) | CA2472746A1 (de) |
| DE (1) | DE60309829T2 (de) |
| ES (1) | ES2276038T3 (de) |
| WO (1) | WO2003059899A1 (de) |
Families Citing this family (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1467982B8 (de) | 2002-01-14 | 2007-04-11 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon |
| EP1490317A1 (de) * | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid-mimetika, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen, und ihre verwendungen |
| JP4324480B2 (ja) * | 2002-03-26 | 2009-09-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメティクス、その製法、医薬組成物、及び使用 |
| US7186864B2 (en) * | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) * | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| NZ538932A (en) * | 2002-08-29 | 2007-04-27 | Boehringer Ingelheim Pharma | 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease |
| EP1583745A1 (de) * | 2003-01-03 | 2005-10-12 | Boehringer Ingelheim Pharmaceuticals Inc. | 1-propanol- und 1-propylaminderivate undderen verwendung als glucocorticoidliganden |
| US20040224992A1 (en) * | 2003-02-27 | 2004-11-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| CA2531060A1 (en) * | 2003-07-01 | 2005-01-13 | Schering Aktiengesellschaft | Heterocyclically-substitued pentanol derivatives, process for their production and their use as anti-inflammatory agents |
| US20050090559A1 (en) * | 2003-07-01 | 2005-04-28 | Markus Berger | Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| UY28526A1 (es) * | 2003-09-24 | 2005-04-29 | Boehringer Ingelheim Pharma | Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos |
| JP4468369B2 (ja) * | 2003-10-16 | 2010-05-26 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | ある種のトリフルオロメチル置換アルコールの立体選択的合成 |
| US7795272B2 (en) * | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
| EP1730145A1 (de) * | 2004-03-22 | 2006-12-13 | Boehringer Ingelheim Pharmaceuticals Inc. | Alpha-trifluormethylalkohole oder -amine als glucocorticoidmimetika |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| PE20060776A1 (es) | 2004-12-27 | 2006-09-26 | Boehringer Ingelheim Pharma | Mimeticos de glucocorticoides, metodos para prepararlos y composiciones farmaceuticas |
| JP5281291B2 (ja) | 2005-01-10 | 2013-09-04 | グラクソ グループ リミテッド | 新規化合物 |
| UY29439A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| MY145281A (en) | 2005-03-25 | 2012-01-13 | Glaxo Group Ltd | Novel compounds |
| NZ564696A (en) * | 2005-06-10 | 2011-05-27 | Boehringer Ingelheim Int | Glucocorticoid, indazole, mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7408060B2 (en) | 2005-06-24 | 2008-08-05 | Schering Ag | Nonsteroidal progesterone receptor modulators |
| DE102005030293A1 (de) * | 2005-06-24 | 2007-01-04 | Schering Ag | Verwendung von nichtsteroidale Progesteronrezeptor-Modulatoren |
| DE102005030294A1 (de) * | 2005-06-24 | 2007-01-04 | Schering Ag | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
| US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
| AU2006324090B2 (en) * | 2005-12-09 | 2012-05-31 | F. Hoffmann-La Roche Ag | Propionamide compounds as antiinflammatory agents |
| PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
| EA200801997A1 (ru) | 2006-04-20 | 2009-04-28 | Глаксо Груп Лимитед | Новые соединения |
| GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
| CA2650478C (en) * | 2006-07-07 | 2013-08-13 | Bausch & Lomb Incorporated | Compositions comprising a dissociated glucocorticoid receptor agonist and an immunosuppressive agent for treating dry eye |
| CA2660151C (en) | 2006-08-07 | 2012-04-17 | Bausch & Lomb Incorporated | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof |
| KR20090050091A (ko) | 2006-08-31 | 2009-05-19 | 보오슈 앤드 롬 인코포레이팃드 | 녹내장 또는 그의 진행을 치료 또는 예방하기 위한 조성물 및 방법 |
| US20110104159A1 (en) * | 2006-09-11 | 2011-05-05 | Rohrs Brian R | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy |
| US20110105559A1 (en) * | 2006-09-11 | 2011-05-05 | Rohrs Brian R | Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy |
| PT2061444E (pt) * | 2006-09-11 | 2011-07-08 | Bausch & Lomb | Composições e métodos de tratamento, controlo, redução, melhoramento ou prevenção de alergias |
| GB0620385D0 (en) * | 2006-10-13 | 2006-11-22 | Glaxo Group Ltd | Novel compounds |
| US7968577B2 (en) | 2006-11-01 | 2011-06-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| MX2009005264A (es) | 2006-12-06 | 2009-05-28 | Boehringer Ingelheim Int | Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos. |
| UY30805A1 (es) * | 2006-12-21 | 2008-07-31 | Bayer Schering Pharma Ag | Moduladores no esteroides de receptores de progesterona |
| AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
| US20090042936A1 (en) * | 2007-08-10 | 2009-02-12 | Ward Keith W | Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation |
| US20090087443A1 (en) * | 2007-09-27 | 2009-04-02 | Bartels Stephen P | Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery |
| WO2009069736A1 (ja) * | 2007-11-28 | 2009-06-04 | Kyowa Hakko Kirin Co., Ltd. | 含窒素化合物 |
| DE102007058747A1 (de) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| US20090239836A1 (en) * | 2008-03-24 | 2009-09-24 | Mary Lee Ciolkowski | Multifunctional Ophthalmic Compositions |
| US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
| JP5791500B2 (ja) | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ,エルエルシー. | 5−リポキシゲナーゼ活性化タンパク質阻害剤 |
| WO2009147190A1 (en) | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| EP2280946B1 (de) | 2008-06-05 | 2016-02-10 | Glaxo Group Limited | Als p13-kinasehemmer nutzbare 4-carboxamid-indazol-derivate |
| DK2300472T3 (da) * | 2008-06-06 | 2012-04-10 | Boehringer Ingelheim Int | Glucocorticoidmimetika, fremgangsmåder til disses fremstilling, farmaceutiske sammensætninger samt anvendelser deraf |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| US8354539B2 (en) | 2009-03-10 | 2013-01-15 | Glaxo Group Limited | Indole derivatives as IKK2 inhibitors |
| JP2012520845A (ja) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Itk阻害剤として使用されるピリミジン誘導体 |
| US20120035247A1 (en) | 2009-03-19 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| AU2010226604A1 (en) | 2009-03-19 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing |
| US20120029054A1 (en) | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
| JP2012520683A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた結合組織増殖因子(CTGF)遺伝子発現のRNA干渉媒介性阻害 |
| WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2010111468A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
| US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| EP2411517A2 (de) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | Rna-interferenz-vermittelte hemmung der genexpression von icam-1 (intercellular adhesion molecule 1) unter verwendung von sina (short interfering nucleic acid) |
| US20110077270A1 (en) * | 2009-04-21 | 2011-03-31 | Pfeffer Bruce A | Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure |
| WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| US8399436B2 (en) | 2009-04-24 | 2013-03-19 | Glaxo Group Limited | N-pyrazolyl carboxamides as CRAC channel inhibitors |
| RS53830B1 (sr) | 2009-04-30 | 2015-06-30 | Glaxo Group Limited | Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze |
| US20110130591A1 (en) | 2009-06-03 | 2011-06-02 | Boehringer Ingelheim International Gmbh | Steroselective synthesis of certain trifluoromethyl-substituted alcohols |
| US20110130578A1 (en) | 2009-06-03 | 2011-06-02 | Boehringer Ingelheim International Gmbh | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols |
| US20110130567A1 (en) | 2009-06-03 | 2011-06-02 | Boehringer Ingelheim International Gmbh | Steroselective synthesis of certain trifluoromethyl-substituted alcohols |
| US20100312013A1 (en) | 2009-06-03 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Steroselective synthesis of certain trifluoromethyl-substituted alcohols |
| EP2507231A1 (de) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazolderivate als pi3-kinaseinhibitoren |
| WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
| WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
| US20120272951A1 (en) | 2009-12-16 | 2012-11-01 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
| WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
| GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
| US9126997B1 (en) * | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
| EP2613781B1 (de) | 2010-09-08 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Indazolderivate für die behandlung von influenzavireninfektionen |
| HRP20151017T1 (hr) | 2010-09-08 | 2015-10-23 | Glaxosmithkline Intellectual Property Development Limited | Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida |
| WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| JP5795643B2 (ja) | 2010-10-21 | 2015-10-14 | グラクソ グループ リミテッドGlaxo Group Limited | アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物 |
| WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
| US20120316199A1 (en) * | 2011-06-07 | 2012-12-13 | Ward Keith W | Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain |
| KR20160060100A (ko) | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| EP3057588A1 (de) | 2013-10-17 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Pi3k-hemmers zur behandlung von atemwegserkrankungen |
| KR20160062179A (ko) | 2013-10-17 | 2016-06-01 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 호흡기 질병의 치료를 위한 pi3k 억제제 |
| US9399637B2 (en) | 2014-03-28 | 2016-07-26 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
| EP3347097B1 (de) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora |
| GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| EP3497100A1 (de) | 2016-08-08 | 2019-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Chemische verbindungen |
| GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
| WO2019099311A1 (en) | 2017-11-19 | 2019-05-23 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| EP3740468B1 (de) | 2018-01-20 | 2025-12-31 | Sunshine Lake Pharma Co., Ltd. | Substituierte aminopyrimidinverbindungen und verfahren zur verwendung |
| CA3173172A1 (en) | 2020-03-26 | 2021-09-30 | Christopher D. Kane | Cathepsin inhibitors for preventing or treating viral infections |
| WO2025147657A1 (en) * | 2024-01-05 | 2025-07-10 | Board Of Trustees Of Michigan State University | Methods for treating alopecia |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8402755A (nl) | 1983-09-22 | 1985-04-16 | Sandoz Ag | Azool-derivaten, werkwijze voor het bereiden daarvan, preparaten die ze bevatten, en toepassing daarvan. |
| GB8406000D0 (en) | 1984-03-07 | 1984-04-11 | Ici Plc | Olefine derivatives |
| GB8617653D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
| GB8617652D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
| US5039691A (en) * | 1989-06-08 | 1991-08-13 | Marion Merrell Dow Inc. | 5-(1-(imidazol)methyl)-3,3-disubstituted-2(3H)furanone derivatives |
| AU717251B2 (en) | 1994-12-22 | 2000-03-23 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| WO1997027852A1 (en) | 1996-01-30 | 1997-08-07 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| DE19723722A1 (de) * | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| KR20010040935A (ko) | 1998-02-13 | 2001-05-15 | 스티븐 에프. 웨인스톡 | 글루코코르티코이드 선택적인 소염제 |
| DE19856475A1 (de) | 1998-11-27 | 2000-05-31 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| PL207610B1 (pl) | 1999-04-30 | 2011-01-31 | Pfizer Prod Inc | Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny |
| US6329534B1 (en) * | 1999-09-01 | 2001-12-11 | Abbott Laboratories | Glucocorticoid receptor antagonists for treatment of diabetes |
| US6436986B1 (en) * | 1999-09-01 | 2002-08-20 | Abbott Laboratories | Glucocorticoid receptor antagonists for treatment of diabetes |
| DE10038639A1 (de) * | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| US6583180B2 (en) * | 2001-02-14 | 2003-06-24 | Abbott Laboratories | Glucocorticoid receptor modulators |
| DE60233111D1 (de) | 2001-02-14 | 2009-09-10 | Karobio Ab | Glucocorticoid-rezeptoren-modulatoren |
| EP1467982B8 (de) | 2002-01-14 | 2007-04-11 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon |
| EP1490317A1 (de) * | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid-mimetika, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen, und ihre verwendungen |
| JP4324480B2 (ja) * | 2002-03-26 | 2009-09-02 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | グルココルチコイドミメティクス、その製法、医薬組成物、及び使用 |
| US7186864B2 (en) * | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) * | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| NZ538932A (en) * | 2002-08-29 | 2007-04-27 | Boehringer Ingelheim Pharma | 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease |
-
2003
- 2003-01-03 EP EP03701228A patent/EP1467982B8/de not_active Expired - Lifetime
- 2003-01-03 CA CA002472746A patent/CA2472746A1/en not_active Abandoned
- 2003-01-03 JP JP2003560002A patent/JP2005519897A/ja active Pending
- 2003-01-03 DE DE60309829T patent/DE60309829T2/de not_active Expired - Fee Related
- 2003-01-03 AU AU2003202216A patent/AU2003202216A1/en not_active Abandoned
- 2003-01-03 US US10/336,340 patent/US6960581B2/en not_active Expired - Lifetime
- 2003-01-03 AT AT03701228T patent/ATE346058T1/de not_active IP Right Cessation
- 2003-01-03 WO PCT/US2003/000300 patent/WO2003059899A1/en not_active Ceased
- 2003-01-03 ES ES03701228T patent/ES2276038T3/es not_active Expired - Lifetime
-
2005
- 2005-10-05 US US11/243,746 patent/US7189758B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6960581B2 (en) | 2005-11-01 |
| US20030232823A1 (en) | 2003-12-18 |
| EP1467982B8 (de) | 2007-04-11 |
| JP2005519897A (ja) | 2005-07-07 |
| EP1467982A1 (de) | 2004-10-20 |
| DE60309829T2 (de) | 2007-09-13 |
| EP1467982B1 (de) | 2006-11-22 |
| CA2472746A1 (en) | 2003-07-24 |
| DE60309829D1 (de) | 2007-01-04 |
| WO2003059899A1 (en) | 2003-07-24 |
| US7189758B2 (en) | 2007-03-13 |
| AU2003202216A1 (en) | 2003-07-30 |
| ES2276038T3 (es) | 2007-06-16 |
| US20060030561A1 (en) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60309829D1 (de) | Glucocorticoid mimetika, verfahren zu ihrer herstellung, pharmazeutische formulierungen sie enthaltend und verwendungen davon | |
| DE60322713D1 (de) | Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung | |
| ECSP055611A (es) | Compuestos miméticos de glucocorticoides, métodos de prepararlos, composiciones farmacéuticas | |
| MY135423A (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| WO2004075864A3 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| WO2005095401A8 (en) | Alpha-trifluoromethyl alcohols or amines as glucocorticoid mimetics | |
| NO20085077L (no) | Nye forbindelser | |
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| WO2005090336A8 (en) | 2-propanol and 2-propylamine derivatives and their use as glucocorticoid ligands | |
| ATE383358T1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| NO20100827L (no) | Glukocorticoid-mimetica, fremgangsmater for fremstilling av dem, farmasoytiske blandinger, og anvendelser derav | |
| TNSN05278A1 (en) | Inhibitors of phosphatidylinositol 3-kinase | |
| WO2006104826A3 (en) | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | |
| NO20055688L (no) | Organiske forbindelser | |
| WO2004100865A3 (en) | New benzimidazole derivatives | |
| TW200633698A (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| ATE386725T1 (de) | Heterocyclylverbindungen | |
| DE602004009200D1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
| SE0402925D0 (sv) | Novel Compounds | |
| BRPI0409376A (pt) | derivados de indeno como agentes farmacêuticos | |
| ATE406363T1 (de) | Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten | |
| SE0403118D0 (sv) | New compounds 2 | |
| WO2006005611A3 (en) | Glucocorticoid 16alpha,17.alpha.-isoxazolidines as anti-inflammatory agents | |
| SE0403117D0 (sv) | New compounds 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1467982 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |